Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program
Launched by FUDAN UNIVERSITY · Nov 26, 2022
Trial Information
Current as of January 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help detect colorectal cancer early by looking for specific markers in blood and stool samples. Colorectal cancer is becoming more common, but early screening can help prevent it and improve treatment outcomes. Unfortunately, many people do not get screened as recommended, especially through colonoscopies. This trial aims to use a modern technique that checks for 5-hydroxymethylcytosine (5-hmC) in blood and DNA changes in stool to identify individuals at higher risk for colorectal cancer. If you are over 50 and under 75 years old, have had a positive result from a colorectal cancer risk questionnaire or a stool test, you might be eligible to participate.
If you join the trial, you will provide blood and stool samples for testing. If your results indicate a higher risk, you will be encouraged to have a colonoscopy, which is a procedure that allows doctors to examine the inside of your colon. This study is important because it aims to improve the rate of early detection of colorectal cancer and make screening more accessible for those at risk. Your participation could help advance our understanding of colorectal cancer screening and potentially save lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 50 years old and\<75 years old;
- • The initial screening was positive (fecal occult blood or colorectal cancer risk questionnaire was positive); ③ Receive sample collection; ④ Sign the informed consent form.
- Exclusion Criteria:
- • ① History of colorectal cancer, colorectal adenoma, and treatment;
- • Enteroscopy was performed after the initial screening was positive; ③ The subject or family members could not understand the conditions and objectives of the study or refused to participate in the study.
Trial Officials
Jianmin Xu, M.D., PhD
Principal Investigator
Fudan University
About Fudan University
Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials